Navigation Links
Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
Date:1/20/2010

THE WOODLANDS, Texas, Jan. 20 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus.  LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.  LX4211, dosed as a single agent, provided improvements in glycemic control, demonstrating statistically significant benefits in the primary and multiple secondary efficacy endpoints.

"Results from this important first trial of LX4211 in diabetic patients exceeded our expectations," said '/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
2. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
3. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
4. Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
5. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
6. Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
7. Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema
8. Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
9. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
10. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
11. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- MHG Medical ... has launched its Medical Equipment and X-ray ... services are tailored to the cruise industry,s unique ... industry operators to propose that they should develop ... new program is intended to create standardized processes ...
(Date:7/29/2014)... July 29, 2014  Instrumentation Laboratory (IL) today announced the ... corporate logo. This is part of a comprehensive rebranding effort ... in Boston, MA , in 1959, IL ... since 1992.  Other companies in the group include Inova Diagnostics ... ( Barcelona, Spain ).  Like IL, these three ...
(Date:7/29/2014)... Cynosure, Inc. (Nasdaq: ... aesthetic treatment systems for high-volume applications, today reported financial ... Second-quarter 2014 financial results incorporate the acquisition of Palomar ... Second-Quarter 2014 Financial Highlights ... million , Non-GAAP net income of $7.1 million, ...
Breaking Medicine Technology:MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12
... PHILADELPHIA, November 10 , ... of Excellence in Serving,Healthcare Needs of Patients in California, ... Elsevier ( http://www.elsevier.com ), a world leader ... that Trinity Health,( http://www.trinity-health.org ), the nation,s fourth largest ...
... SAN DIEGO, Nov. 9 Volcano Corporation (Nasdaq: ... sales of products for the diagnosis and treatment of ... will be participating in the Third Annual Canaccord Cardiovascular ... Scott Huennekens, president and chief executive officer, will begin ...
Cached Medicine Technology:Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 2Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 3Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 4Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 2
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Decorative contact lenses may ... careful, they can cause serious eye damage. Decorative ... ophthalmologist, according to the U.S. Food and Drug Administration ... a valid prescription for these lenses and buy them ... spread the word about the potential health risks associated ...
(Date:7/29/2014)... Penn State College of Medicine, have jointly received ... health data research network., The Patient-Centered Outcomes Research ... Protection and Affordable Care Act, awarded the funds ... and Johns Hopkins University -- and each of ... come together to create a Clinical Data Research ...
(Date:7/29/2014)... July 29, 2014 July 29, 2014 – ... care, is proud to announce that it is a Bronze ... online video segments; Silverado Through a Child's Eye ... , In Silverado Through a Child's Eye , seven-year-old ... mom at Silverado Beverly Place, a memory care community in ...
(Date:7/29/2014)... BC (PRWEB) July 29, 2014 According ... http://www.idataresearch.com ), the leading global authority in medical device ... will grow to over $8 billion by ... advancement, particularly in the transcatheter heart valve market, which ... (THVI) and the transcatheter mitral valve repair (TMVR) segments. ...
(Date:7/29/2014)... WA (PRWEB) July 29, 2014 According ... marijuana in both the recreational and the medicinal sectors ... As legalized marijuana becomes more accepted in mainstream culture, ... drug aside from the traditional and more dangerous forms ... products are becoming quite the trend in legalized states ...
Breaking Medicine News(10 mins):Health News:It's 'Buyer Beware' for Decorative Contact Lenses, FDA Says 2Health News:New network unites university health care research 2Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 3Health News:Marijuana Edibles Sales Show Growth in Market 2
... PARK, Fla., May 18 Transitions Optical, Inc.,today announced ... relevant information about eye health issues through SMS text ... have the option to subscribe to,receive valuable advice and ... eyes to see better today and in the future. ...
... Washinton DC (18 May 2009) Research published this week ... the annual costs of autism spectrum disorder (ASD) to be ... children with ASDs were estimated to be 2.7 billion per ... be presented at the Autism & Employment Workshop taking place ...
... MEI,s Broad Solution Offerings CORAL SPRINGS, Fla., May ... of The MEI Healthcare Group, announced today a ... GE ), a leading provider of healthcare technology. ... customers the option of MEI,s broad solutions, including ...
... by Shire to Patients Taking Lialda(R) (mesalamine) or Pentasa(R) ... Lost Their Jobs in 2009PHILADELPHIA, May 18 Shire ... global specialty biopharmaceutical company, is responding to the needs ... and prescribed gastrointestinal (GI) medications from Shire by expanding ...
... season; experts less sure about global outlook , , MONDAY, May ... raising critical questions about the timing of bringing a new ... the people who need it. , If vaccine manufacturers shift ... seasonal influenza vaccine, experts say. If they wait too long, ...
... blast injuries have become the signature injuries. These can ... damage to the visual system and the visual processing centers ... with them." Gregory Goodrich, Ph.D., Veterans, Administration Research Psychologist, on ... N.Y., May 18 The journey home is a bittersweet ...
Cached Medicine News:Health News:SMS Technology Places Eye Health Educational Information at Hispanics' Fingertips 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 3Health News:MEI Development Corporation and GE Healthcare Sign Strategic Agreement 2Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 2Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 3Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 4Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 5Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:Becoming Aware of Veterans' Vision Needs 2
Multi-constituent normal and abnormal plasma controls for routine and specialty assays performed on the STA© family of hemostasis analyzers....
PT, PTT, Fibrinogetn & TT Normal and Abnormal Controls...
Fructosamine Calibrator...
ApolipoproteinA-1 & B Calibrator...
Medicine Products: